AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis: Paris Friday, January 23, 2026, 14:00 Hrs [IST] AB Science SA, a pharmaceutica ...
AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.
Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing ...
PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT ...
A trial found six weeks of yoga improved sleep quality and reduced fatigue in people with MS, suggesting its use as a ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...
Dementia is a term used to describe memory loss, impaired reasoning, difficulties communicating and other mental impairments ...
Looking for your next TV obsession? Channel 4 is about to deliver it in the form of its creepy new mystery thriller Careless.
Swiss pharma giant Roche Holding AG's RHHBY 2025 results were affected by currency headwinds. Sales totaled $74.4 billion, which missed the Zacks Consensus Estimate of $81.4 billion. Earnings per ...
The series is based on the award-winning novel written by Chris Hammer and follows journalist Martin Scarsden as he ...
[BASEL] Novartis forecast a profit decline for 2026, as some of the Swiss drugmaker’s top sellers – such as the heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results